Podcasts about Progressive supranuclear palsy

Progressive supranuclear palsy and corticobasal syndrome are closely related neurodegenerative disorders that present with progressive parkinsonism and multiple other features that overlap clinically and neuropathologically. Early recognition is critical to provide appropriate treatment and supportive care. In this episode, Teshamae Monteith, MD, FAAN speaks with Nikolaus R. McFarland, MD, PhD, FAAN, author of the article “Progressive Supranuclear Palsy and Corticobasal Syndrome” in the Continuum® August 2025 Movement Disorders issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. McFarland is an associate professor of neurology at the University of Florida College of Medicine at the Norman Fixel Institute for Neurological Diseases in Gainesville, Florida. Additional Resources  Read the article: Progressive Supranuclear Palsy and Corticobasal Syndrome Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Monteith: Hi, this is Dr Teshamae Monteith. Today I'm interviewing Dr Nikolaus McFarland about his article on progressive supranuclear palsy and cortical basilar syndrome, which appears in the August 2025 Continuum issue on movement disorders. Welcome, how are you? Dr Farland: I'm great. Thank you for inviting me to do this. This is a great opportunity. I had fun putting this article together, and it's part of my passion. Dr Monteith: Yes, I know that. You sit on the board with me in the Florida Society of Neurology and I've seen your lectures. You're very passionate about this. And so why don't you first start off with introducing yourself, and then tell us just a little bit about what got you interested in this field. Dr Farland: I'm Dr Nicholas McFarlane. I'm an associate professor at the University of Florida, and I work at the Norman Fixel Institute for Neurological Diseases. I am a director of a number of different centers. So, I actually direct the cure PSP Center of Care and the MSA Center of Excellence at the University of Florida; I also direct the Huntington's clinic there as well. But for many years my focus has been on atypical parkinsonisms. And, you know, I've treated these patients for years, and one of my focuses is actually these patients who suffer from progressive supranuclear palsy and corticobasal syndrome. So that's kind of what this review is all about. Dr Monteith: You probably were born excited, but I want to know what got you interested in this in particular? Dr Farland: So, what got me interested in this in particular was really the disease and the challenges that's involved in it. So, Parkinson's disease is pretty common, and we see a lot of that in our clinic. Yet many times, roughly about 10 to 15% of my patients present with these atypical disorders. And they're quite fascinating. They present in different ways. They're fairly uncommon. They're complex disorders that progress fairly rapidly, and they have multiple different features. They're sort of exciting to see clinically as a neurologist. I think they're really interesting from an academic standpoint, but also in the standpoint of really trying to bring together sort of a team. We have built a multidisciplinary team here at the University of Florida to take care of these patients. They require a number of folks on that team to take care of them. And so, what's exciting, really, is the challenge of treating these patients. There are very limited numbers of therapies that are available, and the current therapies that we have often really aren't great and over time they fail. And so, part of the challenge is actually doing research. And so, there's actually a lot of new research that's been going on in this field. Recently, there's been some revisions to the clinical criteria to help diagnose these disorders. So, that's really what's exciting. The field is really moving forward fairly rapidly with a number of new diagnostics, therapeutics coming out. And hopefully we can make a real difference for these patients. And so that's what really got me into this field, the challenge of trying to treat these patients, help them, advocate for them and make them better. Dr Monteith: And so, tell me what the essential points of this article. Dr Farland: So, the essential points, really, of this article is: number one, you know, just to recognize the new clinical criteria for both PSP and corticobasal syndrome, the diagnosis for these disorders or the phenotypic spectrum has really expanded over the years. So, we now recognize many different phenotypes of these disorders, and the diagnosis has gotten fairly complicated. And so, one of the goals of this article was to review those new diagnostic criteria and the different phenotypic ways these diseases present. I wanted to discuss, also, some of the neuropathology and clinicopathological overlap that's occurred in these diseases as well as some of the new diagnostic tests that are available. That's definitely growing. Some of the new studies that are out, in terms of research and clinical trials. And then wanted to review some of the approaches for treatment for neurologists. Particularly, we're hoping that, you know, this article educates folks. If you're a general neurologist, we're hoping that recognizing these diseases early on will prompt you to refer these patients to specialty clinics or movement disorder specialists early on so they can get appropriate care, confirm your diagnosis, as well as get them involved in trials if they are available. Dr Monteith: And how has the clinical criteria for PSP and cortical basilar syndrome changed? Dr Farland: I think I already mentioned there's been an evolution of the clinical criteria for PSP. There's new diagnostic criteria that were recently published, and it recognizes the multiple clinical phenotypes and the spectrum of the disease that's out there, which is much broader than we thought about. Corticobasal clinical criteria are the Dr Armstrong criteria from 2013. They have not been updated, but they are in the works of being updated. But it does recognize the classic presentation of corticobasal syndrome, plus a frontal executive predominant and then a variant that actually overlaps with PSP. So, there's a lot more overlap in these two diseases than we originally recognized. Dr Monteith: And so, you spoke a bit about FTD spectrum. So why don't you tell us a little bit about what that is? I know you mentioned multiple phenotypes. Dr Farland: What I really want to say is that both PSP and corticobasal syndrome, they're relatively rare, and what- sort of as to common features, they both are progressive Parkinson disorders, but they have variable features. While they're commonly associated with Parkinson's, they also fit within this frontotemporal lobar spectrum, having features that overlap both clinically and neuropathologically. I just want folks to understand that overlap. One of this pathological overlap here is the predominant Tau pathology in the brain, an increasing recognology- recognition of sort of the pathological heterogeneity within these disorders. So, there's an initial description, a classic of PSP, as Richardson syndrome. But now we recognize there are lots of different features to it and there are different ways it presents, and there's definitely a lot of clinical pathological overlap. Dr Monteith: Why don't we just talk about some red flags for PSP? Dr Farland: Yeah, sure. So, some of the red flags for PSP and even corticobasal syndrome are: number one is rapid progression with early onset of falls, gait difficulty, falling typically backwards, early speech and swallow problems that are more prominent than you see in Parkinson's disease, as well as eye gaze issues. So, ocular motor features, particularly vertical gaze palsy. In particular what we talk about is the supranuclear gaze palsy, and one of the most sensitive features that we've seen with these is downgaze limitation or slowed downgaze, and eventually a full vertical gaze palsy and followed supranuclear gaze palsy. So, there's some of the red flags that we see. So, while we think about the lack of response to levodopa frequently as something that's a red flag for Parkinson's, there are many times that we see Parkinson's patients, and about a quarter of them don't really respond. There's some features that don't respond to levodopa that may not be so specific, but also can be helpful in this disease. Dr Monteith: And what about the red flags for cortical basilar syndrome? Dr Farland: So, for cortical basilar syndrome, some of the red flags again are this rapidly depressive syndrome tends to be, at least in its classical present presentation, more asymmetric in its presentation of parkinsonism, with features including things like dystonic features, okay? For limb dystonia and apraxias---so, inability to do a learned behavior. One of those red flags is a patient who comes in and says, my hand doesn't work anymore, which is something extremely uncommon that you hear in Parkinson's disease. Most of those patients will present, say, I might have a tremor, but they very rarely will tell you that I can't use my hand. So look out for that sign. Dr Monteith: And let's talk a little bit about some of the advances in the fields you mentioned, evolving biomarker and imaging capacities. So, how are these advances useful in helping us understand these conditions, especially when there's so much heterogeneity? Dr Farland: I might start by talking a little bit about some of the clinical criteria that have advanced. Why don't we start there and just discuss some of the advances? I think in PSP, I think, originally we had both probable and possible diagnoses of PSP, and the diagnostic criteria were basically focused on what was what's called “classical PSP” or “Richardson syndrome”. But now we recognize that there are multiple phenotypes. There's an overlap with Parkinsonism that's slower in progression and morphs into PSP, the classical form. There's a frontal behavioral variant where patients present with that frontal behavioral kind of thing. There's a speech-language variant that can overlap with PSP. So they have prominent speech language, potentially even apraxia speech. So, recognition of these different phenotypes is sort of a new thing in this field. There's even overlap with cortical basal syndrome and PSP, and we note that the pathology can overlap as well. So, I think that's one of the things that have changed over time. And these were- recently came out in 2017 in a new publication in the Movement Disorders Society. So, in terms of diagnostic tests as well---and there's been quite a bit of evolution---really still to date, our best diagnostic test is imaging. MRI is really one of our best tests currently. Currently blood tests, spinal fluid, there's new biomarkers in terms of skin… they're still in the research phase and not necessarily very specific yet. So, we rely heavily on imaging still; and for PSP, what we're looking for largely are changes in the brain stem, and particularly focused on the midbrain. So disproportionate midbrain atrophy compared to the pons and the rest of the midbrain is a fairly specific intensive sign for PSP. Whereas in MSA we see more of a pontine atrophy compared to the midbrain. So that can be really helpful, and there are lots of different new measurements that can be done. PET scans are also being used as well. And there are new PET markers, but they still remain kind of research-based, but are becoming more and more prevalent and may be available soon for potential use. Although there's some overlap with PET tracers with Alzheimer's disease and different Tau isoforms. So, something to be wary about, but we will be seeing some of these soon coming out as well. More kind of up-to-date things include things like the spinal fluid as well as even some of the skin biopsies. And I think we've heard some word of recent studies that have come out that potentially in the very near future we might actually have some Tau protein tests that we can look at Tau either in spinal fluid or even in a skin biopsy. But again, still remains research-based and, we still need more information as to whether these tests can be reproducible and how sensitive or specific they are. Dr Monteith: It sounds like, when really approaching these patients, still, it's a lot of back to the history, back to the clinical and some basic imaging that we should be able to identify to distinguish these types of patients, and we're not quite where we need to be yet for biomarker. Dr Farland: I totally agree with you. I think it starts, really, with the clinical exam and that's our main focus here; and understanding some of the new clinical criteria which are more sensitive, but also specific, too. And they're really useful to look at. So, I think reviewing those; patients do progress, following them over time can be really useful. And then for diagnosis, getting imaging if you suspect a patient has an atypical presentation of parkinsonism, to look for signs or features that might be specific for these different disorders. Dr Monteith: Why don't we take a typical case, a typical patient that you would see in clinic, and walk us through the thought process---especially, maybe they presented somewhat early---and the different treatment approaches to helping the patient, and of course their family. Dr Farland: Yeah, sure. So, a typical patient might be someone who comes in with, like, a three year history of progressive gait problems and falling. And let's say the patient says, I'm falling backwards frequently. They may have had, like, a rib fracture, or they hit their head once, and they're describing some speech issues as well. Now they're relying on a walker and family members saying they rarely let them be by themselves. And there may be some slowing of their cognitive function and maybe a bit of withdrawal. So that's a typical patient. So, the approach here is really, what are some of the red flags? I think already you hear a red flag of a rapidly progressive disease. So, Parkinson's disease patients rarely have frequent falls within the first five years. So, this is within three years or less. You're already hearing early onset of gait problems and falling, and particularly falling backwards rather than forwards as often Parkinson's disease patients do. You're hearing early speech problems and maybe a subtle hint of cognitive slowing and some withdrawal. So, a lot of things that sort of are red flags. So, our approach really would be examining this patient really closely. Okay? We'd be listening to the history, looking at the patient. One thing is that some of these patients come in, they may be in a wheelchair already. That's a red flag for us. If they're wearing sunglasses---sometimes we see that patients, they have photosensitivity and they're in a chair and they're wearing sunglasses---you take the glasses off and you look at their face and they have that sort of a facial stare to them---not just the masked face, but the stare---and their eyes really aren't moving. So, another kind of clue, maybe this is probably something atypical, particularly PSP is what I'm thinking about. So, the approach is really, do a thorough exam. I always recommend looking at eye movements and starting with volitional saccades, not giving them a target necessarily, but asking them to look up and then look down. And then particularly look at the speed of downgaze and whether they actually have full versions down, are able to do that. That's probably your most sensitive test for a patient who has PSP. Not the upgaze, which can be- upgaze impairment in older patients can be nonspecific. So, look for that down gaze. So, if I can get out one message, that's one thing that can be easily done and examined fairly quickly for diagnosis of these patients. And then just look for signs of rigidity, bradykinesia, maybe even some myelopraxia, and then look at their gait carefully so that there's a high suspicion. Again, if there's some atypical features, imaging is really important. So, my next step would be probably getting an MRI to evaluate whether- do they have brain somatrophy or other widespread atrophy or other signs? You need to think about your differential diagnosis for some of these patients as well. So, common things are common; vascular disease, you can't have vascular parkinsonism or even signs of NPH. Both of those can present with progressive gait difficulty and falls. So, the gait may look more like Parkinson's rather than ataxic gait that we see in classic PSP, but still they have early gait issues, and that can be a mimicker of PSP, So looking for both of those things in your imaging. Think about sort of autoimmune potentially causes. So, if they have a really rapid progressive cause, there are some rare autoimmune things. There have been recent reports of things like IgLON5, although there's limited cases, but we're doing more screening for some of those autoimmune causes. And then even some infectious causes like Whipples, that are rarely present like this. Okay? And have other signs and features. Dr Monteith: So, let's say you diagnose this patient with PSP and you're assessing the patients to see how you can improve their quality of life. So, what are some potential symptomatic managements that will help our patient? Dr Farland: I recommend for most all of these patients… while the literature indicates that many patients with PSP, and especially corticobasal syndrome, don't respond well to levodopa. So, the classic treatment for parkinsonism. However, we all recommend a trial of levodopa. These patients may respond partially to doses of levodopa, and we try to push the doses a bit higher. So, the recommended trial is usually a dose up to roughly 1000 milligrams of levodopa per day. And give it some time, at least two, if not actually three months of a trial. If not well-tolerated, you can back off. If there's no response at all or no improvement, then slowly back off and taper patients off and ask them to tell you whether they feel like they're actually worsening. So, many patients, sometimes, don't recognize the improvements, or family members don't recognize it until we actually taper them back off. And they may end up saying there are some other things that even recognize. Even some nonmotor benefits can be seen with levodopa. In some cases, we do keep them on levodopa, but levodopa's our best therapy for this. Dopamine agonists, MAO inhibitors, have all been sort of tried and they've been studied, but often don't really help or fail to help benefit these patients and could be fraught with some other side effects. I think many people do also turn to Amantadine as a treatment for Parkinson's, gait problems, freezing, if you see it in these disorders. Yet Amantadine is fraught with issues of side effects, including cognitive issues, and I think is not well-tolerated. But there are the rare patient who actually does respond to this or claims they respond to this. By and large, these patients relentlessly progress, unfortunately. So, beside treatment of other symptoms, I think it's really important to recognize that they require supportive cares and therapy. So, starting those early on and getting your allied healthcares kind of involved. So that includes people like physical, occupational therapy for the gait issues, the falls, occupational therapy for doing daily activities. Speech language pathology can be really a critical player for these because of the early speech and language issues, as well as swallow difficulties. Swallow is compared quickly in these patients. And so, we do recommend the screening evaluation, then often following patients either every six- or even annually, at least, with a swallow evaluation. And we recommend the fluoroscopic-guided kind of modified barium swallow for these patients.  Dr Monteith: And how does that differ if, let's say, the patient had cortical basilar syndrome? What are some of the symptomatic treatments that would be high on your consideration? Dr Farland: So actually, these patients also have a very similar approach, and they often have some overlapping features. Maybe a little bit of difference in terms of the level of apraxia and some dystonic features that you see in corticobasal syndrome. So, as I mentioned earlier that these patients have a more typ- when they present, typically have a more asymmetric presentation. And one of the biggest issues is this limb apraxia. They may have abnormal movements as well as, like, the alien limb-type phenomena as well. So, the focus of therapy, while similar in the sense we focus on the parkinsonism, I do always try levodopa and try to ramp up the doses to see if it benefits. It does often fail, but it's definitely worth trying. The other focus of these patients is trying to treat symptoms. Dystonia, those features… in some cases, we can help; if it's painful or uncomfortable, muscle relaxants can be used. If it's vocal, things like Botox can be really helpful. Often times it is more palliative than actually restorative in terms of function, but still can be really helpful for patients who ask about pain and discomfort and trying to treat. And then of course, again, the focus on our supportive care. We need to build that network and build that team of folks, the therapists, the physical, occupational, and the speech therapist to help them. If they have language problems---like either in PSP or corticobasal---I'll also include my request to a speech language pathologist to work on cognitive function. That's a special, additional thing you have to ask for and then specifically request when you make a referral to a speech language pathologist. Dr Monteith: That is so important. I think keeping the simulation, keeping the social support, and I would probably guess that you would also include screening for sleep and mood disorder. Dr Farland: Absolutely. Mood disorders are really big in these diseases. Patients are suffering terribly. You do hear about labile mood in both of these diseases, particularly PSP; and even what's called pseudobulbar palsy, where the mood is not always congruent with the affect. So they may laugh or cry inappropriately, and particularly the crying can be very disturbing to family and caregivers to see that. And so, treating those things can be really important. So always asking about the mood issues. Depression in particular is something that we're very sensitive about, and there is a higher incidence of suicidal ideations. Asking about that and feeling and making sure that they are in a safe environment can be really important. Dr Monteith: Thank you so much. Dr Farland: Thank you. Dr Monteith: Today I've been interviewing Dr Nikolaus McFarland about his article on progressive supranuclear palsy and cortical basilar syndrome, which appears in the August 2025 Continuum issue on movement disorders. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Dr. Eduardo de Pablo-Fernández discusses and Dr Tommaso Schirinzi discuss the results of his study evaluating markers of immune response, metabolism, inflammatory regulation and tau levels in blood cells in patients with progressive supranuclear palsy (PSP). They also discuss how these results contribute to the growing evidence of neuroinflammation contributing to the pathogenesis of PSP. Journal CME is available until October 21, 2025 Read the article.

Dr. Edwin Jabbari, a 2024 MDS Junior Award Winner, joins the MDS Podcast to share the results of his award-winning work on the development of a 4-repeat tau SAA and what led him to this work. He also shares helpful tips for other junior researchers.

It's Friday, July 26th, A.D. 2024. This is The World View in 5 Minutes, written by yours truly and heard at www.TheWorldView.com. Filling in for Adam McManus, I'm Ean Leppin. Hope emerging in Indonesia International Christian Concern, or the ICC, reports that residents living near the Tesalonika Church in Indonesia rioted and demanded that the church cease its worship activities. The footage of the rioters went viral on social media this week. A representative of the church stated that the church had been gathering inside a home because their lease for their previous place of worship had expired. Churches that meet in larger cities in Indonesia can generally worship openly; however, churches in smaller villages are increasingly challenged, threatened, and attacked. The ICC goes on to say, “Muslims are increasingly leaving Islam to follow Jesus, and devoted Muslims are taking notice. At the same time, religious tolerance is increasing in Indonesia and some churches are finally gaining approval to construct their own buildings after years and even decades of waiting.” Please pray to praise God for the growth of Christianity in Indonesia and to give boldness and strength for those who continue to face persecution. Jesus prayed for the church in John 17:16-19: “They are not of the world, just as I am not of the world. Sanctify them in the truth. As you sent me into the world, so I have sent them into the world. And for their sake I consecrate myself, that they also may be sanctified in truth.” Pro-life groups branded terrorists? Are pro-life Americans and groups branded as terrorists by the US Army? In a word … yes. Lifenews.com reported that journalist Sam Shoemate exposed a terrorism briefing held at Fort Liberty where they listed several pro-life organizations as terrorist organizations. Shoemate posted this on X on July 10th. They specifically named US Right to Life and Operation Rescue as terrorist organizations. The military facility has since recalled the slide that was in the presentation and revised it. In their own post on X, they said, “After conducting a commander's inquiry, we determined that the slides presented on social media were not vetted by the appropriate authorities, and do not reflect the views of the XVIII Airborne Corps and Fort Liberty, the US Army or the Department of Defense. These slides will no longer be used, and all future training products will be reviewed to ensure they align with the current DoD anti-terrosism guidance.” Ted Budd, a senator from North Carolina, issued a letter in response on July 12th, saying, “The Army must fully renounce this attack on pro-life Americans and conduct a full investigation to ensure similar materials aren't being used at other installations.” It has been revealed that these slides have been in use for the past 7 years at Fort Liberty. Articles of impeachment filed against Kamala Harris WGN News reports that six Democrats have joined House Republicans in voting to condemn the Biden administration and Vice President Kamala Harris in her role as US border czar. Earlier this year, GOP Lawmakers impeached Homeland Security Secretary Alejandro Mayorkas for his failure to secure the border. Representative Andy Ogles from Tennessee has filed articles of impeachment against Harris. In an interview with Fox News Representative Ogles said this. CLIP: "We have a crisis…failure" Ogles goes on to say that this is not only his duty, but that time is also of the essence! CLIP: "I have an oath…if you will" Romans 13:1-2 says, “Let every person be subject to the governing authorities. For there is no authority except from God, and those that exist have been instituted by God. Therefore whoever resists the authorities resists what God has appointed, and those who resist will incur judgment.” First US House member to deliver floor speech using AI voice clone As reported by AP News, a rare neurological disorder called Progressive Supranuclear Palsy, or PSP, took the voice of Representative Jennifer Wexton from Virginia. A new AI technology made it possible for her to speak before the House on Thursday! Rep Wexton spoke as a voice for other people with disabilities during Disability Pride Month. She also became the first House member in history to speak using an AI clone of her own voice. Here is part of her statement. CLIP: "I also never…so much more" Boy in foster care allowed to stay with disabled brother Finally, reported on Good news network.org, Dawson and his older brother Dalton were two brothers who were in the foster system together. Staying together was very important to Dawson because his brother Dalton has cerebral palsy, epilepsy, is non-verbal, and a quadriplegic. Keeping them together in the adoption process would be very challenging! But thanks to the Dave Thomas Foundation for Adoption, a couple from Florida, and the grace of God, the boys are now together and in a new home with a loving family. That couple is Steven and Robbin. Robbin says that she couldn't have asked for better sons. She says, “Dawson is the person he is because he got the opportunity to keep his brother. It's half of him-that's his heart.” As for Dawson, he wants to grow up to be a doctor so that he can take care of people that have needs similar to that of his big brother. Close And that's The World View on this Friday, July 26th, in the year of our Lord 2024. Subscribe by iTunes or email to our unique Christian newscast at www.TheWorldView.com. Or, get the Generations app through Google Play or The App Store. Seize the day for Jesus Christ.

LINKS:Pod Virginia | PatreonLearn more about Jackleg MediaCheck out Black Virginia NewsIN THE NEWS:If you're looking for an example of a recount that changed the results of an election, you'll have to go all the way back to Indiana, 1985. Here in Virginia, recounts have been conducted in three congressional elections since 1967, and none of them changed the outcome--but Bob Good in the 5th District is pushing for one anyway.With the aid of AI, Congresswoman Jennifer Wexton has regaied her voice; trained up on her public speeches, the AI voice sounds much like Wexton did before she was silenced by Progressive Supranuclear Palsy, and she says this tool could be life-changing for Americans with disabilities.The rapid rise of fentanyl overdoses is causing concern among lawmakers, although they are not yet on the same page about how to handle the situation.That's why the General Assembly created a new task force to consider the policy choices and how they would work. For example, how much does an individual need to have to be prosecuted as a dealer versus helped as a patient suffering from substance abuse disorder? TRIVIA: What is the statewide recount that did not happen because the loser couldn't afford the $120,000 price tag?At the Watercooler:- The Democrats are still trying to figure out if Biden will be their nominee- The 1932 Democratic convention, where Harry Byrd tried to unseat Franklin RooseveltLearn more at http://linktr.ee/JacklegMedia

In this second installment of our series on rare neurologic diseases, host Katy McGraw talks with Heather Cianci about Progressive Supranuclear Palsy (PSP), a neurologic disease that can mimic some features of Parkinson Disease (PD) like loss of balance and a tendency to fall backwards, but that also has unique features such as the loss of vertical gaze, and behavioral changes. Heather discusses clinical signs to look for to treat and/or refer out for. She also talks extensively about treating PSP clinically throughout the disease course, palliative care for patients with advanced PSP, working within interdisciplinary teams to support patients with PSP, and so much more.   Enjoying our new series on rare neurologic diseases? We want to hear from you! Give us feedback, share ideas for future podcasts, and connect us to expert clinicians treating patients with those diseases. Email us at: neuroddsig@gmail.com  The Degenerative Diseases Special Interest Group is part of the Academy of Neurologic Physical Therapy – www.neuroPT.org  Show notes available: https://app.box.com/s/59dhwr9i0p29p4hrkxjnvbdyxl8kh94m

This episode features an interview with Dr. Lahar Mehta, Head of Global Clinical Development at Amylyx Pharmaceuticals, who spoke to Xtalks about Amylyx's clinical trial design of ORION, a Phase III Global Study of AMX0035 (Relyvrio) in Progressive Supranuclear Palsy (PSP). The company presented details about the trial at the Neuro2023 PSP and CBD International Research Symposium that took place in London last month in October. The ORION study will evaluate the safety, efficacy, and tolerability of AMX0035 in PSP patients. The drug was approved by the FDA last year for the treatment of ALS.PSP is a rare, progressive, adult-onset neurological disorder that affects body movements, walking and balance, eye movement, swallowing, and speech. There are currently no approved medicines to treat PSP. Hear more about the details of the trial, which is set to begin in December this year.For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Gunter Hoglinger, MD, professor of neurology and translational neuroscientist at Ludwig Maximillian's University Munich, provided commentary on a newly initiated phase 3 study assessing AMX0035 (Relyrvio; Amylyx Pharmaceuticals) in patients with progressive supranuclear palsy (PSP). Otherwise known as the ORION trial, Hoglinger discussed what went into trial inclusion, primary end points, and why they believe this therapy, which was approved for patients with amyotrophic lateral sclerosis (ALS) in 2022, could have benefits in PSP.  Looking for more neuromuscular disorder discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:15 – Underlying mechanisms of progressive supranuclear palsy 3:30 – Similarities and differences between ALS and PSP 5:00 – Overview of ORION study design 7:00 – Neurology News Minute 9:15 – Reasons behind specific trial inclusion 10:35 – Primary end points of the study  12:50 – Significance of a potentially successful trial This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Advisory Committee Downvotes Mesenchymal Stem Cell Approach NurOwn as Potential ALS Therapy FDA Approves HoneyNaps' Artificial Intelligence Sleep Disorder Diagnosis Software FDA Approves Cipaglucosidase Alfa and Miglustat as First Two-Component Therapy for Pompe Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

What direction will the field of PSP research go in the years to come? Prof. Gunter Höglinger sits down with Dr. Eduardo Fernandez at the MDS Congress to help answer that very question. 2023 Congress virtual access

#mentalhealth #PSP # ProgressiveSupranuclearPalsy #phantompain #dudleymoore Jay Gunkelman is the EEG Tech Legend that has read well over 500,000 Brain scans and he joins Pete Jansons on the NeuroNoodle Neurofeedback Podcast to discuss Progressive Supranuclear Palsy PSP Dudley Moore Disease as well as phantom pain Key Moments 0:00 1:56 Progressive Supranuclear Palsy PSP Dudley Moore Disease 3:32 Tauopathy, Parkinson's, Palsy, Alzheimer's, Steele-Richardson-Olszewski syndrome 6:32 What is Tau 7:38 Basal Ganglia 7:40 Substantial Nigra 8:00 Personality Changes 8:35 Axial Rigidity, Weighted Walker, Shoes no heels 10:17 Levodopa, L-Dopa 10:52 Will anything show on EEG? Where does disease start in brain? 12:02 Is Progressive Supranuclear Palsy PSP related to Parkinson's? 12:58 Can Neurofeedback help with symptoms? 13:46 Stimulations, Photobiomodulation, Alzheimer's 14:30 TCE Trichloroethylene Solvents 18:17 Chemical Burns, East Palestine Ohio Train Derailment 19:40 Progression of Progressive Supranuclear Palsy PSP 22:34 Barry Sterman 22:50 Parkinson's Stimulation 24:10 Phantom Pain Screen Share 26:42 Tinnitus Screen Share 28:20 Reward deficiency syndrome, Depression --- Send in a voice message: https://anchor.fm/neuronoodle/message Support this podcast: https://anchor.fm/neuronoodle/support

Existing somewhere in the space between Empire and Annie Live!, the television musical is a  powerful elixir, capable of twisting up your entire emotional constitution with less than a minute of the ol' song-and-dance. You might think musicals are corny, but also...I don't know anyone who doesn't enjoy corn. It's corn!  Spoiler season begins around the 34 minute mark, so soft shoe carefully past that point if you're unfamiliar with the show being discussed (Zoey's Extraordinary Playlist).If you need a gut punch, here's the link to the scene from Glee I mentioned in the episode: https://www.youtube.com/watch?v=TlWHTfrGhoY. And if that's not enough, here's Max from Zoey's Extraordinary Playlist singing "Anyone" (which I now know is the name of that song...special shout out to my Second Opinion): https://www.youtube.com/watch?v=Q_ctGtvz8bA&t=5s.Speaking of my awesome Second Opinion Brandi Nicole, feel free to gag over her accolades and accomplishments here: https://www.imdb.com/name/nm3759443/?ref_=nv_sr_srsg_0 .And finally, please consider learning more about Progressive Supranuclear Palsy and supporting the research for its cure by visiting https://www.PSP.org.

Are Omicron-specific booster shots more effective than the original boosters? Find out about this and more in today's PV Roundup podcast.

In part 3 of a 3-part series, Alexander Pantelyat, MD, FAAN, discusses his article, "Progressive Supranuclear Palsy and Corticobasal Syndrome" from the October Continuum Movement Disorders issue. This article and the accompanying Continuum Audio interview are available to subscribers at continpub.com/PSPCBD. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In part 2 of a 3-part series, Alexander Pantelyat, MD, FAAN, discusses his article, "Progressive Supranuclear Palsy and Corticobasal Syndrome" from the October Continuum Movement Disorders issue. This article and the accompanying Continuum Audio interview are available to subscribers at continpub.com/PSPCBD. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In part 1 of a 3-part series, Alexander Pantelyat, MD, FAAN, discusses his article, "Progressive Supranuclear Palsy and Corticobasal Syndrome" from the October Continuum Movement Disorders issue. This article and the accompanying Continuum Audio interview are available to subscribers at continpub.com/PSPCBD. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Dr. Tampton is a 4th year neurology resident and the incoming fellow at the Medical College of Wisconsin. He will be starting his neurocritical fellowship in the spring of 2022.

And the primary caregiver.

At some time in our lives, we will all be caregivers or will receive care from others. Dr. Larry Studt talks with host Lisa Wells of the Aging and Disability Resource Center of Eau Claire County about his own caregiving journey. Larry's wife, Rachel, experienced a rare form of young onset dementia, Progressive Supranuclear Palsy, which unexpectedly thrust him into a caregiving role. Larry talks about the challenges this created, the emotions and guilt that come with caregiving, the importance of accepting help, the need for self-care, and the search for hope.

MJ (Mary Jane) Grant shares with us how being a proud CODA (Child Of Deaf Adults) defined her life purpose – translating and interpreting the human heart.  For MJ, being a CODA wasn't “pain” or “struggle,” but the world is not set up to support deaf people. People would call her parents dumb, and now caring for her mother with dementia, she's risen up to share the very real experience and challenge with others in a documentary. She will open and break your heart and show you how to persevere with joy, grit, and purpose. You will LOVE her and this episode! It's a fact that no one is exempt from going through tough times. More often than we'd like we find ourselves dealing with really difficult situations than can be frustrating and unfair, making us feel powerless. But even though most of us may fall into these negative ways of feeling, we ALSO can find truly meaningful gifts hidden among the adversity.   In this episode, MJ and I laugh (she's become a good friend), we cry, we dish on joy and rollerblading and all things to rise up from trauma. She's a lifelong learner who grew up with a passion for connection and skillful, nuanced communication, excelling in the daily work of connecting others while opening hearts along the way. In this episode, MJ and I discuss the following: The importance of accepting yourself -and HOW to accept yourself – plus how not doing so can lead to identity struggle, depression or worse. How to overcome external judgements. How to turn hard situations into fertilizer for personal growth. An upcoming new paradigm that embraces difference and accepts everybody as special in a unique way. Regardless of how hopeless a context may seem, remember – you always get to choose! Watch “So Happy to Meet You”, the short documentary MJ did for the International Dementia Conference that was founded by HammondCare in Australia (https://youtu.be/3py3DHOfW2w). You can check out the journey she has documented at her Instagram and Twitter account (@mjgrant) and also at her YouTube channel (https://www.youtube.com/channel/UC4eyyELBabLfNrHMsEeBNMg). Want more PurposeGirl?? Ready to be your full Goddess on Purpose self? And desire Sisterhood who feels the same? Join the Free PurposeGirls Facebook Group! I post prompts, motivation, and do free live videos and challenges to get you on purpose and loving life!! Join here! https://www.facebook.com/groups/PurposeGirlsGroup/ Also make sure you're getting my newsletter – that's the first place I send announcements about events, programs and share purpose and happiness tips. https://carinrockind.com/newsletter Love this episode? Love The PurposeGirl Podcast? Then share the love!! Go to Apple Podcasts and leave a 5 star review, subscribe so you never miss an episode, and download ALL the episodes to listen again and again! And share the PurposeGirl Podcast with every woman you know – that's how we change the world one woman at a time!! Thank you so much for listening, love, and if you aren't following me already, you can find me on Instagram and Facebook. May you live purposefully, may you love yourself, and may you love life!! Bye for now! XO, Carin About Mary Jane Grant Mary Jane Grant AKA MJ came into the world with a magical curiosity for life. Born to two Deaf parents in Sanford, Maine, MJ is a lifelong learner who excels in the daily work of connecting others while opening hearts along the way. She is a proud CODA (Child Of Deaf Adults) and a native user of American Sign Language (ASL), who grew up with a passion for connection and skillful, nuanced communication. MJ has learned, loved and thrived through every chance encounter with the individuals she has met along the way. Her joyful, intuitive nature reflects a warmhearted tenderness and instinctual resilience that emerged early in life and led to a career as a professional sign language interpreter. She has worked with Deaf communities across the U.S. while managing her company, Mary Jane Grant Sign Language Interpreting Services, in between moments of happy chaos at home. But her real gift in the most simple terms? She translates and interprets the human heart. In recent years, MJ walked alongside her father, who passed in 2019, after his battle with Progressive Supranuclear Palsy while being the primary caregiver for her mother who is living with dementia. Having navigated the healthcare system, MJ discovered the tremendous barriers to care for Deaf seniors. It is MJ's mission to open the hearts of others and ensure her mother, Carmen, as well as every other Deaf senior, has access to the highest quality care to live their best life possible.

Mari interviews Linda Ronstadt (singer-songwriter) & Dr. Ish Major (Psychiatrist, Relationship Coach, “Marriage Boot Camp”). Linda talks about her Mexican heritage and traditions in the documentary, “Linda and the Mockingbirds.” Her thoughts on immigration and the mental toll and trauma for children separated from their families at the border, racism, and importance of making a difference in this world. How she’s living with progressive supranuclear palsy, her favorite books, and her life during the pandemic. Next, the preacher of love, Dr. Ish Major on choosing the love we deserve, the once habit to make you fall more in love with yourself, dealing with shame, and getting to acceptance. How our scars make us beautiful. “Be brave, ask for help, and be persistent in finding the mental help that you need.” For free or affordable mental help, visit: http://checkyourheadpodcast.com/* DONATE to our mission at checkyourheadpodcast.com or on our patreon.com page. Every dollar is appreciated, every listener is appreciated

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.10.196097v1?rss=1 Authors: Rebecca R Valentino, Nikoleta Tamvaka, Michael G Heckman, Patrick W Johnson, Alexandra I Soto-Beasley, Ronald L Walton, Shunsuke Koga, Ryan J Uitti, Zbigniew K Wszolek, Dennis W Dickson, Owen A Ross Abstract: Mitochondrial health is important in ageing and dysfunctional oxidative phosphorylation (OXPHOS) accelerates ageing and influences neurodegeneration. Mitochondrial DNA (mtDNA) codes for vital OXPHOS subunits and mtDNA background has been associated with neurodegeneration; however, no study has characterised mtDNA variation in Progressive supranuclear palsy (PSP) or Corticobasal degeneration (CBD) risk or pathogenesis. In this case-control study, 916 (42.5% male) neurologically-healthy controls, 1051 (54.1% male) pathologically-confirmed PSP cases, and 173 (51.4% male) pathologically-confirmed CBD cases were assessed to determine how stable mtDNA polymorphisms, in the form of mtDNA haplogroups, were associated with risk of PSP, risk of CBD, age of PSP onset, PSP disease duration, and neuropathological tau pathology measures for neurofibrillary tangles (NFT), neuropil threads (NT), tufted astrocytes (TA), and oligodendroglial coiled bodies (CB). 767 PSP cases and 152 CBD cases had quantitative tau pathology scores. mtDNA was genotyped for 39 unique SNPs using Agena Bioscience iPlex technologies and mitochondrial haplogroups were defined to mitochondrial phylogeny. After adjustment for multiple testing, we observed a significant association with risk of CBD for mtDNA sub-haplogroup H4 (OR=4.49, P=0.001) and the HV/HV0a haplogroup was associated with a decreased severity of NT tau pathology in PSP cases (P=0.0023). Our study reports that mitochondrial genomic background may be associated with risk of CBD and may be influencing tau pathology measures in PSP. Replication of these findings will be important.Competing Interest StatementZKW serves as PI or Co-PI on Abbvie, Inc. (M15-562 and M15-563), Biogen, Inc. (228PD201) grant, and Biohaven Pharmaceuticals, Inc. (BHV4157-206 and BHV3241-301). He serves as PI of the Mayo Clinic American Parkinson Disease Association (APDA) Information and Referral Center, and as Co-PI of the Mayo Clinic APDA Center for Advanced Research. All other authors declare that they have no competing interests. No competing interests are reported by other authors. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.06.16.154757v1?rss=1 Authors: Bachmann, S., Bell, M., Klimek, J., Zempel, H. Abstract: In the adult human brain, six isoforms of the microtubule-associated protein TAU are expressed, which result from alternative splicing of exons 2, 3 and 10 of the MAPT gene. These isoforms differ in the number of N-terminal inserts (0N, 1N, 2N) and C-terminal repeat domains (3R or 4R) and are differentially expressed depending on the brain region and developmental stage. Although all TAU isoforms can aggregate and form neurofibrillary tangles, some tauopathies, such as Pick's Disease and Progressive Supranuclear Palsy, are characterized by the accumulation of specific TAU isoforms. Many studies focused on the role of TAU in these diseases, however only few addressed isoform-specific functions of TAU in healthy and under pathological conditions. In this report, we investigated the subcellular localization of the human-specific TAU isoforms in primary mouse neurons. Our results show that 2N-TAU isoforms are particularly retained from axonal sorting and that axonal enrichment is independent from the number of repeat domains. Furthermore, we analyzed TAU isoform-specific effects on cell area and microtubule dynamics in SH-SY5Y neuroblastoma cells and observed a general reduction of cell size and an increase of microtubule counts in cells expressing 4R-TAU isoforms. Our study points out TAU isoform-specific effects that will be addressed in follow-up studies to unravel if and how TAU isoforms contribute to cellular functions in health and disease. Copy rights belong to original authors. Visit the link for more info

Marilyn and Glen Heavilin have shared a joyful and adventurous life together for 61 years while also experiencing the tragic loss of 3 children—two infants and one 17 yr. old son killed by a drunk driver. Marilyn's book, Roses in December, touches the heart of grievers seeking help and comfort. Pray for Marilyn—her present diagnosis is Progressive Supranuclear Palsy. These two continue to model love, marriage and commitment as they seek God's help to deal with health challenges. Incredible interview with the Heavilins. Listen now! To support this Life affirming ministry, please join us by setting up a monthly gift here. It makes a huge difference for the radio ministry.

In this interview with Dr. Jabbari we highlight the results of his study on the definition and genetic and neuropathological characteristics of early onset progressive supranuclear palsy. The full study is available on the September 2019 issue of the Movement Disorders Journal.

Go online to PeerView.com/YPK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the symptoms, diagnosis, and management of patients with progressive supranuclear palsy, focusing on pathophysiology, detection, and therapeutic approaches currently under investigation. Upon completion of this activity, participants should be better able to: Identify patients with progressive supranuclear palsy based on their presentation, symptoms, and laboratory test results, Assess the potential benefits and clinical shortcomings of current symptomatic and supportive care approaches for patients with progressive supranuclear palsy, Cite available data and ongoing trials on emerging tau-targeted therapies for the treatment of progressive supranuclear palsy, Recognize the potential impact of emerging tau-targeted therapies on the future management of progressive supranuclear palsy.

Go online to PeerView.com/YPK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the symptoms, diagnosis, and management of patients with progressive supranuclear palsy, focusing on pathophysiology, detection, and therapeutic approaches currently under investigation. Upon completion of this activity, participants should be better able to: Identify patients with progressive supranuclear palsy based on their presentation, symptoms, and laboratory test results, Assess the potential benefits and clinical shortcomings of current symptomatic and supportive care approaches for patients with progressive supranuclear palsy, Cite available data and ongoing trials on emerging tau-targeted therapies for the treatment of progressive supranuclear palsy, Recognize the potential impact of emerging tau-targeted therapies on the future management of progressive supranuclear palsy.

Go online to PeerView.com/YPK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the symptoms, diagnosis, and management of patients with progressive supranuclear palsy, focusing on pathophysiology, detection, and therapeutic approaches currently under investigation. Upon completion of this activity, participants should be better able to: Identify patients with progressive supranuclear palsy based on their presentation, symptoms, and laboratory test results, Assess the potential benefits and clinical shortcomings of current symptomatic and supportive care approaches for patients with progressive supranuclear palsy, Cite available data and ongoing trials on emerging tau-targeted therapies for the treatment of progressive supranuclear palsy, Recognize the potential impact of emerging tau-targeted therapies on the future management of progressive supranuclear palsy.

Go online to PeerView.com/YPK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the symptoms, diagnosis, and management of patients with progressive supranuclear palsy, focusing on pathophysiology, detection, and therapeutic approaches currently under investigation. Upon completion of this activity, participants should be better able to: Identify patients with progressive supranuclear palsy based on their presentation, symptoms, and laboratory test results, Assess the potential benefits and clinical shortcomings of current symptomatic and supportive care approaches for patients with progressive supranuclear palsy, Cite available data and ongoing trials on emerging tau-targeted therapies for the treatment of progressive supranuclear palsy, Recognize the potential impact of emerging tau-targeted therapies on the future management of progressive supranuclear palsy.

Pharmaceutical companies do not have our best interest at heart. Board-certified cardiologist Dr. Jack Wolfson gets the information out to the world about how we can achieve the best in heart health and do so naturally. In this inaugural episode, Dr. Wolfson talks about his father's battle with Progressive Supranuclear Palsy, and how he was following the exact same footsteps of an unhealthy lifestyle before meeting the woman who would change all that. He also gives a sneak peek of what his future shows hold – entertaining and educational interviews with fantastic guests. Discover the gift of health and wellness as Dr. Wolfson talks about the different ways for you to achieve your best life.

Jennifer Levin was a caregiver  for her father who had Progressive Supranuclear Palsy, a rare degenerative brain disease.  Since then, she has gone on to write about her experience as a Millenial caregiver for Cosmopolitan and created and moderate the Caregiver Collective support group on Facebook.  Jennifer's goal is to bring awareness to the startling statistic of Millenials who care for family, the ways caregiving affects them differently than previous generations, as well as encourage these caregivers to seek support. We discuss a range of issues ranging from the specific challenges that Millennial caregivers face, why it's so important to identify as a caregiver and how to handle job pressures and advocate for your rights as a caregiver. You can connect with Jennifer on her Facebook Support Group - CaregiverCollective and through Twitter - @classiclevin. --- Send in a voice message: https://anchor.fm/caring-conversations/message

Jennifer Levin was a caregiver  for her father who had Progressive Supranuclear Palsy, a rare degenerative brain disease.  Since then, she has gone on to write about her experience as a Millenial caregiver for Cosmopolitan and created and moderate the Caregiver Collective support group on Facebook.  Jennifer's goal is to bring awareness to the startling statistic of Millenials who care for family, the ways caregiving affects them differently than previous generations, as well as encourage these caregivers to seek support. We discuss a range of issues ranging from the specific challenges that Millennial caregivers face, why it's so important to identify as a caregiver and how to handle job pressures and advocate for your rights as a caregiver. You can connect with Jennifer on her Facebook Support Group - CaregiverCollective and through Twitter - @classiclevin. --- Send in a voice message: https://anchor.fm/caring-conversations/message

Jennifer Levin was a caregiver for her father who had Progressive Supranuclear Palsy, a rare degenerative brain disease. Since then, she has gone on to write about her experience as a Millenial caregiver for Cosmopolitan and created and moderate the Caregiver Collective support group on Facebook. Jennifer's goal is to bring awareness to the startling statistic of Millenials who care for family, the ways caregiving affects them differently than previous generations, as well as encourage these caregivers to seek support.We discuss a range of issues ranging from the specific challenges that Millenial caregivers face, why it's so important to identify as a caregiver and how to handle job pressures and advocate for your rights as a caregiver.You can connect with Jennifer on her Facebook Support Group - CaregiverCollective and through Twitter - @classiclevin.

New Yorker Jennifer Levin talks about how becoming a caregiver for her father at age 32 changed her and why she wrote about her experience in Cosmopolitan digital magazine. Initially diagnosed with Parkinson's disease, Jennifer's father was eventually diagnosed with Progressive Supranuclear Palsy (PSP), a degenerative brain disease. Jennifer reflects on why her social media posts remained cheery even as she struggled offline with caring for her father, she tells us why she was reluctant to join a support group and why there's a stark difference between being a Millennial or Gen-X caregiver versus caregiving as a baby boomer. She pushes back on the stereotype of young adults as being lazy and mooching off their parents, and tells us why being a bossy New Yorker is helpful advocating on behalf of caregivers. Jennifer's article for Cosmopolitan digital: http://bit.ly/2kpgfoG “Caregiver Collective” private Facebook page for Millennial caregivers: http://bit.ly/2mMf0Be More about Progressive Supranuclear Palsy (PSP): http://mayocl.in/2mfLK9t Music: “Wounds” (remix) by Ketsa | CC BY NC ND | Free Music Archive

Adam Boxer offers an overview of the latest on diagnosis and treatment for progressive supranuclear palsy.

Show description/summary:1) A randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study2) What's Trending: Survival and dementia in GBA-associated Parkinson disease This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 23, 2017 issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Hubert Fernandez about his paper on deutetrabenazine for tardive dyskinesia. For our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Roberto Cilia about his Annals of Neurology paper on survival and dementia in GBA-associated Parkinson disease. Disclosures can be found at Neurology.org. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Barrett receives research support from Axovant Sciences, Inc., Azevan Pharmaceuticals, Merck Sharp & Dohme Corp, Virginia Center of Alzheimer´s and Related Diseases, Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program, and NIH.Dr. Fernandez serves on scientific advisory boards for Solvay Duodopa Global Study, EMD Serono Safinamide Global Study, and the Xeomin Registry (all uncompensated); has received travel or speaker honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape, Biogen GE Healthcare, Lundbeck, and Pfizer; served as Medical Editor for the Movement Disorders Society; co-owns the patent for COMPRESS; receives royalty payments from book publications with Demos Publishing, Manson Publishing, and Springer Publishing; has received research support from AbbVie, Acadia, Teva Pharmaceuticals, Biotie Therapeutics, Civitas, Kyowa Kirin International, Rhythm Pharmaceuticals, Synosia Therapeutics, Abbott, Merz Pharmaceuticals, Xeomin Registry Study, Ipsen Pharmaceuticals, Michael J. Fox Foundation, Movement Disorders Society, Huntington Study Group, Parkinson Study Group, National Parkinson Foundation, Society of Progressive Supranuclear Palsy, and NIH/NINDS.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Cilia receives research support from Fondazione Grigioni per il Morbo di Parkinson.

There is a strong view among adventurous healthcare professionals that Parkinson’s disease is not a distinct, separate “disease”, but one possible set of symptoms arising from one or more causes that create a degenerative process. Other “diseases” that may arise from these causes include Progressive Supranuclear Palsy, Multiple System Atrophy, Motor Neurone Disease/ALS, Osteoarthritis, Osteoporosis, Cardiovascular disease, Alzheimer’s disease, Dementia, Type 2 Diabetes, certain cancers, and many others. When viewed in this way, likely causes become clearer and treatment options widen dramatically. Modern research is now showing significant benefits from “folk medicine” and “old wives’ remedies” like food choices, appropriate hydration, dancing, singing, gentle detoxification activities, self-love and meditation. Let’s look at Parkinson’s disease as a set of symptoms, discover the individual pathway that led each person to this point, and deal with the causes to create wellness. John Coleman ND is author of Stop Parkin' and Start Livin'.  Visit his website: www.returntostillness.com.au For information about the Aquas visit: www.aquas4life.com  

Last Dance at the Savoy includes a resource guide and, through Scott's experiences, addresses questions such as how do I recognize early warning signs and get proper diagnosis? How do I handle the complex changes and strains in our relationship?Author/Actress Kathryn Leigh Scott has written several books of fiction and nonfiction. She starred in the cult favorite “Dark Shadows” and has recently appeared in a recurring role on “The Goldbergs.” SUBSCRIBE to our YouTube Channel.L!KE us on Facebook.FOLLOW us on Instagram.

Last Dance at the Savoy includes a resource guide and, through Scott’s experiences, addresses questions such as how do I recognize early warning signs and get proper diagnosis? How do I handle the complex changes and strains in our relationship? Author/Actress Kathryn Leigh Scott has written several books of fiction and nonfiction. She starred in the cult favorite “Dark Shadows” and has recently appeared in a recurring role on “The Goldbergs.”  SUBSCRIBE to our YouTube Channel. L!KE us on Facebook. FOLLOW us on Instagram.

Progressive supranuclear palsy (PSP) is a condition that affects the brain with symptoms that worsen over time. Irene Litvan, MD joins William Mobley, MD, PhD to talk about the signs and symptoms of PSP, disease progression, genetic issues, as well as potential treatments on the horizon. Series: "Women in Science" [Health and Medicine] [Science] [Show ID: 30399]

Progressive supranuclear palsy (PSP) is a condition that affects the brain with symptoms that worsen over time. Irene Litvan, MD joins William Mobley, MD, PhD to talk about the signs and symptoms of PSP, disease progression, genetic issues, as well as potential treatments on the horizon. Series: "Women in Science" [Health and Medicine] [Science] [Show ID: 30399]

Special Guest: Lawrence I. Golbe, MD In their early stages, conditions like Progressive Supranuclear Palsy, Multiple System Atrophy and Corticobasal Degeneration closely resemble Parkinson's, but they are actually distinct disease. A discussion about what research into these rare conditions is telling us about what the prospects are for those who suffer from them. To listen to more episodes of this podcast, visit our website: www.worldpdcoalition.org/?page=PortlandCountdown

MDS presents the latest research and findings from the field of Movement Disorders. Abstracts of articles from the Society Journal, Movement Disorders, are taken from the February 2014 (Vol. 29, Issue 2) issue.

MDS presents the latest research and findings from the field of Movement Disorders. Abstracts of articles from the Society Journal, Movement Disorders, are taken from the July 2013 (Vol. 28, Issue 8) issue.

MDS presents the latest research and findings from the field of Movement Disorders. Abstracts of articles from the Society Journal, Movement Disorders, are taken from the April 2013 (Vol. 28, Issue 4) issue.

MDS presents the latest research and findings from the field of Movement Disorders. Abstracts of articles from the Society Journal, Movement Disorders, are taken from the December 2012 (Vol. 27, Issue 14) issue.

MDS presents the latest research and findings from the field of Movement Disorders. Abstracts of articles from the Society Journal, Movement Disorders, are taken from the December 2012 (Vol. 27, Issue 14) issue.

MDS presents the latest research and findings from the field of Movement Disorders. Abstracts of articles from the Society Journal, Movement Disorders, are taken from the June 2012 (Vol. 27, Issue 7) issue.

In This Episode We present The second half Of our Epic conversation with Singer/Songwriter Lance Lapointe In this half, We discuss Star Trek, Childrens Hospital, Progressive Supranuclear Palsy, The Things We Will Do For Our Parents, Fundraisers And Again So Much More! Lance also Performs a couple songs for your listening pleasure Like us on Facebook.com/smalltownbringdown Follow us on Twitter Show @smalltownbring Branden @lunchboxcreates Elliot @thatguyelliot Email: smalltownbringdown@lunchboxfabrications.com

Tauopathies are widespread neurodegenerative disorders characterised by the intracellular accumulation of hyperphosphorylated tau. Especially in Alzheimer's disease, pathological alterations in the retina are discussed as potential biomarkers to improve early diagnosis of the disease. Using mice expressing human mutant P301S tau, we demonstrate for the first time a straightforward optical approach for the in vivo detection of fibrillar tau in the retina. Longitudinal examinations of individual animals revealed the fate of single cells containing fibrillar tau and the progression of tau pathology over several months. This technique is most suitable to monitor therapeutic interventions aimed at reducing the accumulation of fibrillar tau. In order to evaluate if this approach can be translated to human diagnosis, we tried to detect fibrillar protein aggregates in the post-mortem retinas of patients that had suffered from Alzheimer's disease or Progressive Supranuclear Palsy. Even though we could detect hyperphosphorylated tau, we did not observe any fibrillar tau or Aß aggregates. In contradiction to previous studies, our observations do not support the notion that Aβ or tau in the retina are of diagnostic value in Alzheimer's disease.

Background/Aims: Increasing evidence suggests that elevated levels of homocysteine (Hcy) and methylmalonate (MMA) may be involved in the pathogenesis of neurodegenerative diseases. Methods: The urine levels of MMA and serum levels of Hcy as well as folic acid and vitamin B 12 were measured in patients suffering from the distinct neurodegenerative diseases progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), and compared to age-and gender-matched control subjects. Results: We found significantly elevated concentrations of Hcy (PD 15.1, PSP 15.8, ALS 13.9, control 11.2 mu mol/l) and MMA (PD 3.7, PSP 3.1, ALS 3.7, control 1.8 mg/g) in all patient groups in comparison with controls. Levels of Hcy and MMA did not differ significantly between the neurodegenerative diseases. Conclusion: Our findings might imply that Hcy and MMA are released as a consequence of neurodegeneration regardless of the underlying cause and serve as surrogate markers of neurodegeneration. Alternatively they might be directly implicated in the pathogenesis of these diseases. Since elevated levels of both Hcy and MMA are neurotoxic, further studies might investigate the effect of vitamin therapy on disease progression. Copyright (C) 2010 S. Karger AG, Basel